Skip to main content
Equibles

AKUMS · Akums Drugs and Pharmaceuticals Limited · Financials

Use AKUMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AKUMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
740.55 INR -9.90 (-1.32%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 8692 Avg daily vol (3M) 12.94K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
43.59B +5.8%
FY2026 Revenue FY2025–FY2026
Net Income
2.55B -24.5%
FY2026 Net Income FY2025–FY2026
Operating Cash Flow
11.81B +153.9%
FY2026 Operating Cash Flow FY2025–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025
INR 48.26B 43.59B 41.18B
INR 1.64B 1.55B 1.53B
INR 980.68M 940.73M 346M
INR 5.15B 3.82B 3.45B
INR 1.5B 1.26B 14.76M
INR 3.64B 2.55B 3.38B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 0 in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.